Specialist venture firm Dimension Capital has closed an $800 million third fund dedicated to computational biotech, signaling robust investor enthusiasm despite the absence of an FDA-approved AI-designed medicine. The San Francisco and New York-based firm has emerged as one of the sector's most active early-stage backers, leveraging capital shifts away from traditional SaaS business models toward AI-driven life sciences. 

With cheques ranging from under $10 million to $100 million, the fund builds on Dimension’s high-profile portfolio, which includes Earendil Labs ($787 million raise), Chai Discovery, NewLimit, and Coefficient Bio, the latter acquired by Anthropic in April 2026. Dimension’s raise reflects a broader influx of capital into the space, following Andreessen Horowitz’s $700 million biotech-AI vehicle earlier this year. While around 850 AI-developed candidates are currently in development globally, investors are betting that the convergence of top-tier computational talent and pharmaceutical R&D partnerships with giants like Eli Lilly and AstraZeneca will ultimately yield clinical success.

When we asked which therapy area has shaped modern medicine the most, 59% of 142 voters chose oncology. Cardiology followed at 19%, rare disease at 14%, and neurology at 8%.

The audience vote closely matched the Prix Galien USA medal data. Since 2007, oncology has received 24 medals, representing 23% of all awards and nearly one in four medals given. Cardiology follows with 14 medals, or 13%.

The results reflect just how significantly oncology has influenced research, clinical practice, diagnostics, biomarkers, treatment development, and patient care over the past two decades.

While every therapy area has played an important role in advancing medicine, both the poll results and the medal data point to oncology as the clear leader.

Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations and upcoming event.

Indian generics manufacturer Alembic Pharmaceuticals has received a warning letter from the US FDA regarding non-manufacturing infractions. Following an inspection under the Bioresearch Monitoring Program of its Alembic Research Centre Bioequivalence facility in Vadodara, Gujarat, the regulator cited significant deficiencies in how informed consent was obtained during an in vivo bioequivalence trial.

The FDA found that Alembic’s Informed Consent Form (ICF) explicitly asserted that while the trial was a clinical research project, "no part of it is of an experimental nature". The agency noted that this phrasing undermines the informed consent process by obscuring the clinical trial’s experimental nature and the requirement of human subjects from making fully informed decisions.

The warning letter (dated July 10) strictly focuses on clinical protocol and consent governance rather than data integrity or manufacturing quality. Alembic stated that the action does not restrict ongoing facility operations or carry an immediate material financial impact, and the firm is coordinating a response within the mandatory 15-day window.

Nona Biosciences has entered a strategic research collaboration with the Medical University of Vienna (MedUni Vienna). The partnership grants the inter-university Ignaz Semmelweis Institute, headed by infectious disease expert Prof. Florian Krammer, access to Nona’s proprietary ‘H2L2 Harbour Mice’ platform to generate fully human antibodies for infectious disease research, diagnostics, and therapeutics.

MedUni Vienna will leverage Nona's genetically engineered H2L2 Harbour Mice platform. These transgenic models produce classical antibody structures (2 heavy and 2 light chains) with fully human variable and constant regions, bypassing the need for additional in vitro humanization steps. The institute will initially focus on generating and characterizing human mAbs against critical viral targets, such as viral spike proteins, to advance antiviral therapy development and bolster global pandemic preparedness.

MedUni Vienna gains the rights to utilize the platform for antibody generation and development. Ownership of the underlying H2L2 Harbour Mice platform and core IP remains fully retained by Nona Biosciences.

In a significant escalation of US trade policy, the Trump administration has announced plans to implement a 100% tariff on imported generic medicines starting August 2028, with the levy scheduled to double to 200% in August 2029. The policy maintains a two-year zero-tariff grace period designed to compel foreign and domestic drugmakers to establish manufacturing operations within the US.

The announcement triggered immediate declines across major Indian pharmaceutical equities, including Lupin, Natco Pharma, Granules India, Dr. Reddy's Laboratories, and Aurobindo Pharma. India accounts for nearly 40% of US generic drug imports, generating approximately $9.7 billion in export revenue in 2025. Industry analysts and trade bodies contend that relocating low-margin generic production to the US is economically unviable due to high capital expenditure, elevated operating costs, and stringent domestic labor markets.

The impending tariff threat may hasten Indian biopharma’s strategic pivot away from commoditized generics toward high-value, complex assets, including biologics, specialty oncology, and medical devices. Indian companies have already initiated this transition through targeted US acquisitions (e.g. Sun Pharma's buyouts of Organon and Checkpoint Therapeutics) and direct investments into US-based manufacturing infrastructure.